ID   GNAS2_HUMAN             Reviewed;         394 AA.
AC   P63092; A6NI00; E1P5G5; P04895; Q12927; Q14433; Q32P26; Q5JWD2;
AC   Q5JWD4; Q5JWD5; Q6NR75; Q6NXS0; Q8TBC0; Q96H70;
DT   13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT   13-AUG-1987, sequence version 1.
DT   05-OCT-2016, entry version 143.
DE   RecName: Full=Guanine nucleotide-binding protein G(s) subunit alpha isoforms short;
DE   AltName: Full=Adenylate cyclase-stimulating G alpha protein;
GN   Name=GNAS; Synonyms=GNAS1, GSP;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS GNAS-1 AND GNAS-2).
RC   TISSUE=Liver;
RX   PubMed=3093273; DOI=10.1016/0014-5793(86)81336-9;
RA   Mattera R., Codina J., Crozat A., Kidd V., Woo S.L.C., Birnbaumer L.;
RT   "Identification by molecular cloning of two forms of the alpha-subunit
RT   of the human liver stimulatory (GS) regulatory component of adenylyl
RT   cyclase.";
RL   FEBS Lett. 206:36-42(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM GNAS-1).
RX   PubMed=3131741; DOI=10.1093/nar/16.8.3585;
RA   Harris B.A.;
RT   "Complete cDNA sequence of a human stimulatory GTP-binding protein
RT   alpha subunit.";
RL   Nucleic Acids Res. 16:3585-3585(1988).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND ALTERNATIVE SPLICING (ISOFORMS
RP   GNAS-1 AND GNAS-2).
RX   PubMed=3127824; DOI=10.1073/pnas.85.7.2081;
RA   Kozasa T., Itoh H., Tsukamoto T., Kaziro Y.;
RT   "Isolation and characterization of the human Gs alpha gene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:2081-2085(1988).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS GNAS-1 AND GNAS-2).
RA   Puhl H.L. III, Ikeda S.R., Aronstam R.S.;
RT   "cDNA clones of human proteins involved in signal transduction
RT   sequenced by the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM GNAS-1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M.,
RA   Beasley O.P., Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J.,
RA   Buck D., Burrill W.D., Butler A.P., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M., Clark G., Clark L.N., Clark S.Y., Clee C.M.,
RA   Clegg S., Cobley V.E., Collier R.E., Connor R.E., Corby N.R.,
RA   Coulson A., Coville G.J., Deadman R., Dhami P.D., Dunn M.,
RA   Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H.,
RA   Rice C.M., Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S.,
RA   Skuce C.D., Smith M.L., Soderlund C., Steward C.A., Sulston J.E.,
RA   Swann R.M., Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A.,
RA   Tracey A., Tromans A.C., Vaudin M., Wall M., Wallis J.M.,
RA   Whitehead S.L., Whittaker P., Willey D.L., Williams L., Williams S.A.,
RA   Wilming L., Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S.,
RA   Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS GNAS-1; 3 AND 4).
RC   TISSUE=Bone marrow, Brain, Muscle, and Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 12-394 (ISOFORMS GNAS-1 AND 4).
RX   PubMed=3024154; DOI=10.1073/pnas.83.23.8893;
RA   Bray P., Carter A., Simons C., Guo V., Puckett C., Kamholz J.,
RA   Spiegel A., Nirenberg M.;
RT   "Human cDNA clones for four species of G alpha s signal transduction
RT   protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:8893-8897(1986).
RN   [10]
RP   PROTEIN SEQUENCE OF 187-199 AND 308-317.
RC   TISSUE=Adipocyte;
RX   PubMed=15242332; DOI=10.1042/BJ20040647;
RA   Aboulaich N., Vainonen J.P., Stralfors P., Vener A.V.;
RT   "Vectorial proteomics reveal targeting, phosphorylation and specific
RT   fragmentation of polymerase I and transcript release factor (PTRF) at
RT   the surface of caveolae in human adipocytes.";
RL   Biochem. J. 383:237-248(2004).
RN   [11]
RP   FUNCTION.
RX   PubMed=12391161; DOI=10.1128/MCB.22.22.7942-7952.2002;
RA   Pak Y., Pham N., Rotin D.;
RT   "Direct binding of the beta1 adrenergic receptor to the cyclic AMP-
RT   dependent guanine nucleotide exchange factor CNrasGEF leads to Ras
RT   activation.";
RL   Mol. Cell. Biol. 22:7942-7952(2002).
RN   [12]
RP   INTERACTION WITH ADCY5 AND ADCY6, AND FUNCTION.
RX   PubMed=17110384; DOI=10.1074/jbc.M607522200;
RA   Gao X., Sadana R., Dessauer C.W., Patel T.B.;
RT   "Conditional stimulation of type V and VI adenylyl cyclases by G
RT   protein betagamma subunits.";
RL   J. Biol. Chem. 282:294-302(2007).
RN   [13]
RP   INTERACTION WITH CRY1.
RX   PubMed=20852621; DOI=10.1038/nm.2214;
RA   Zhang E.E., Liu Y., Dentin R., Pongsawakul P.Y., Liu A.C., Hirota T.,
RA   Nusinow D.A., Sun X., Landais S., Kodama Y., Brenner D.A.,
RA   Montminy M., Kay S.A.;
RT   "Cryptochrome mediates circadian regulation of cAMP signaling and
RT   hepatic gluconeogenesis.";
RL   Nat. Med. 16:1152-1156(2010).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-352, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [16]
RP   PALMITOYLATION AT CYS-3.
RX   PubMed=21044946; DOI=10.1194/jlr.D011106;
RA   Forrester M.T., Hess D.T., Thompson J.W., Hultman R., Moseley M.A.,
RA   Stamler J.S., Casey P.J.;
RT   "Site-specific analysis of protein S-acylation by resin-assisted
RT   capture.";
RL   J. Lipid Res. 52:393-398(2011).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [18]
RP   INTERACTION WITH ADCY5, AND FUNCTION.
RX   PubMed=26206488; DOI=10.1124/mol.115.099556;
RA   Brand C.S., Sadana R., Malik S., Smrcka A.V., Dessauer C.W.;
RT   "Adenylyl cyclase 5 regulation by Gbetagamma involves isoform specific
RT   use of multiple interaction sites.";
RL   Mol. Pharmacol. 88:758-767(2015).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [20]
RP   VARIANTS AHO PRO-99 AND CYS-165.
RX   PubMed=8388883; DOI=10.1210/jc.76.6.1560;
RA   Miric A., Vechio J.D., Levine M.A.;
RT   "Heterogeneous mutations in the gene encoding the alpha-subunit of the
RT   stimulatory G protein of adenylyl cyclase in Albright hereditary
RT   osteodystrophy.";
RL   J. Clin. Endocrinol. Metab. 76:1560-1568(1993).
RN   [21]
RP   VARIANT MAS HIS-201.
RX   PubMed=1594625; DOI=10.1073/pnas.89.11.5152;
RA   Schwindinger W.F., Francomano C.A., Levine M.A.;
RT   "Identification of a mutation in the gene encoding the alpha subunit
RT   of the stimulatory G protein of adenylyl cyclase in McCune-Albright
RT   syndrome.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:5152-5156(1992).
RN   [22]
RP   VARIANTS MAS CYS-201 AND HIS-201.
RX   PubMed=1944469; DOI=10.1056/NEJM199112123252403;
RA   Weinstein L.S., Shenker A., Gejman P.V., Merino M.J., Friedman E.,
RA   Spiegel A.M.;
RT   "Activating mutations of the stimulatory G protein in the McCune-
RT   Albright syndrome.";
RL   N. Engl. J. Med. 325:1688-1695(1991).
RN   [23]
RP   VARIANTS SOMATOTROPHINOMA CYS-201; HIS-201 AND ARG-227.
RX   PubMed=2549426; DOI=10.1038/340692a0;
RA   Landis C.A., Masters S.B., Spada A., Pace A.M., Bourne H.R.,
RA   Vallar L.;
RT   "GTPase inhibiting mutations activate the alpha chain of Gs and
RT   stimulate adenylyl cyclase in human pituitary tumours.";
RL   Nature 340:692-696(1989).
RN   [24]
RP   VARIANT AHO HIS-385.
RX   PubMed=7523385;
RA   Schwindinger W.F., Miric A., Zimmerman D., Levine M.A.;
RT   "A novel Gs alpha mutant in a patient with Albright hereditary
RT   osteodystrophy uncouples cell surface receptors from adenylyl
RT   cyclase.";
RL   J. Biol. Chem. 269:25387-25391(1994).
RN   [25]
RP   CHARACTERIZATION OF VARIANT PHP1A SER-366.
RX   PubMed=8072545; DOI=10.1038/371164a0;
RA   Iiri T., Herzmark P., Nakamoto J.M., van Dop C., Bourne H.R.;
RT   "Rapid GDP release from Gs alpha in patients with gain and loss of
RT   endocrine function.";
RL   Nature 371:164-168(1994).
RN   [26]
RP   VARIANT NON-MAS ENDOCRINE TUMORS LEU-201.
RX   PubMed=7751320; DOI=10.1007/BF01366965;
RA   Gorelov V.N., Dumon K., Barteneva N.S., Palm D., Roher H.-D.,
RA   Goretzki P.E.;
RT   "Overexpression of Gs alpha subunit in thyroid tumors bearing a
RT   mutated Gs alpha gene.";
RL   J. Cancer Res. Clin. Oncol. 121:219-224(1995).
RN   [27]
RP   VARIANT PITUITARY ADENOMA HIS-227.
RX   PubMed=7737262; DOI=10.1111/j.1365-2362.1995.tb01537.x;
RA   Williamson E.A., Ince P.G., Harrison D., Kendall-Taylor P.,
RA   Harris P.E.;
RT   "G-protein mutations in human pituitary adrenocorticotrophic hormone-
RT   secreting adenomas.";
RL   Eur. J. Clin. Invest. 25:128-131(1995).
RN   [28]
RP   VARIANT PITUITARY TUMOR SER-201.
RX   PubMed=8766942; DOI=10.1530/eje.0.1340720;
RA   Yang I., Park S., Ryu M., Woo J., Kim S., Kim J., Kim Y., Choi Y.;
RT   "Characteristics of gsp-positive growth hormone-secreting pituitary
RT   tumors in Korean acromegalic patients.";
RL   Eur. J. Endocrinol. 134:720-726(1996).
RN   [29]
RP   CHARACTERIZATION OF VARIANT AHO HIS-231, AND FUNCTION.
RX   PubMed=8702665; DOI=10.1074/jbc.271.33.19653;
RA   Farfel Z., Iiri T., Shapira H., Roitman A., Mouallem M., Bourne H.R.;
RT   "Pseudohypoparathyroidism, a novel mutation in the betagamma-contact
RT   region of Gsalpha impairs receptor stimulation.";
RL   J. Biol. Chem. 271:19653-19655(1996).
RN   [30]
RP   VARIANT POLYOSTOTIC FIBROUS DYSPLASIA SER-201.
RX   PubMed=9267696; DOI=10.1016/S8756-3282(97)00107-5;
RA   Candeliere G.A., Roughley P.J., Glorieux F.H.;
RT   "Polymerase chain reaction-based technique for the selective
RT   enrichment and analysis of mosaic arg201 mutations in G alpha s from
RT   patients with fibrous dysplasia of bone.";
RL   Bone 21:201-206(1997).
RN   [31]
RP   VARIANT AHO ARG-250.
RX   PubMed=9328353; DOI=10.1210/me.11.11.1718;
RA   Warner D.R., Gejman P.V., Collins R.M., Weinstein L.S.;
RT   "A novel mutation adjacent to the switch III domain of G(S alpha) in a
RT   patient with pseudohypoparathyroidism.";
RL   Mol. Endocrinol. 11:1718-1727(1997).
RN   [32]
RP   CHARACTERIZATION OF VARIANT AHO HIS-231.
RX   PubMed=9159128; DOI=10.1073/pnas.94.11.5656;
RA   Iiri T., Farfel Z., Bourne H.R.;
RT   "Conditional activation defect of a human Gsalpha mutant.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:5656-5661(1997).
RN   [33]
RP   VARIANT AHO TRP-258, MUTAGENESIS OF ARG-258, AND CHARACTERIZATION OF
RP   VARIANT AHO TRP-258.
RX   PubMed=9727013; DOI=10.1074/jbc.273.37.23976;
RA   Warner D.R., Weng G., Yu S., Matalon R., Weinstein L.S.;
RT   "A novel mutation in the switch 3 region of Gs-alpha in a patient with
RT   Albright hereditary osteodystrophy impairs GDP binding and receptor
RT   activation.";
RL   J. Biol. Chem. 273:23976-23983(1998).
RN   [34]
RP   VARIANT MAS GLY-201.
RX   PubMed=10571700; DOI=10.1359/jbmr.1999.14.11.1987;
RA   Riminucci M., Fisher L.W., Majolagbe A., Corsi A., Lala R.,
RA   De Sanctis C., Robey P.G., Bianco P.;
RT   "A novel GNAS1 mutation, R201G, in McCune-albright syndrome.";
RL   J. Bone Miner. Res. 14:1987-1989(1999).
RN   [35]
RP   MUTAGENESIS OF GLN-170 AND ARG-258.
RX   PubMed=10200251; DOI=10.1073/pnas.96.8.4268;
RA   Warner D.R., Weinstein L.S.;
RT   "A mutation in the heterotrimeric stimulatory guanine nucleotide
RT   binding protein alpha-subunit with impaired receptor-mediated
RT   activation because of elevated GTPase activity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:4268-4272(1999).
RN   [36]
RP   INVOLVEMENT IN PHP1B.
RX   PubMed=11067869; DOI=10.1172/JCI10431;
RA   Liu J., Litman D., Rosenberg M.J., Yu S., Biesecker L.G.,
RA   Weinstein L.S.;
RT   "A GNAS1 imprinting defect in pseudohypoparathyroidism type IB.";
RL   J. Clin. Invest. 106:1167-1174(2000).
RN   [37]
RP   INVOLVEMENT IN PHP1B.
RX   PubMed=11294659; DOI=10.1086/320117;
RA   Bastepe M., Lane A.H., Jueppner H.;
RT   "Paternal uniparental isodisomy of chromosome 20q -- and the resulting
RT   changes in GNAS1 methylation -- as a plausible cause of
RT   pseudohypoparathyroidism.";
RL   Am. J. Hum. Genet. 68:1283-1289(2001).
RN   [38]
RP   INVOLVEMENT IN PHP1B, VARIANT ILE-382 DEL, AND CHARACTERIZATION OF
RP   VARIANT ILE-382 DEL.
RX   PubMed=11029463; DOI=10.1074/jbc.M006032200;
RA   Wu W.-I., Schwindinger W.F., Aparicio L.F., Levine M.A.;
RT   "Selective resistance to parathyroid hormone caused by a novel
RT   uncoupling mutation in the carboxyl terminus of G alpha(s). A cause of
RT   pseudohypoparathyroidism type Ib.";
RL   J. Biol. Chem. 276:165-171(2001).
RN   [39]
RP   VARIANT AHO HIS-231.
RX   PubMed=11450852; DOI=10.1007/s100380170062;
RA   Ishikawa Y., Tajima T., Nakae J., Nagashima T., Satoh K., Okuhara K.,
RA   Fujieda K.;
RT   "Two mutations of the Gsalpha gene in two Japanese patients with
RT   sporadic pseudohypoparathyroidism type Ia.";
RL   J. Hum. Genet. 46:426-430(2001).
RN   [40]
RP   VARIANT AHO LEU-115.
RX   PubMed=11600516; DOI=10.1210/jc.86.10.4630;
RA   Ahrens W., Hiort O., Staedt P., Kirschner T., Marschke C., Kruse K.;
RT   "Analysis of the GNAS1 gene in Albright's hereditary osteodystrophy.";
RL   J. Clin. Endocrinol. Metab. 86:4630-4634(2001).
RN   [41]
RP   VARIANTS PHP1A ASN-156; MET-159 AND LYS-280.
RX   PubMed=11788646; DOI=10.1210/jc.87.1.189;
RA   Linglart A., Carel J.-C., Garabedian M., Le T., Mallet E.,
RA   Kottler M.-L.;
RT   "GNAS1 lesions in pseudohypoparathyroidism Ia and Ic: genotype
RT   phenotype relationship and evidence of the maternal transmission of
RT   the hormonal resistance.";
RL   J. Clin. Endocrinol. Metab. 87:189-197(2002).
RN   [42]
RP   VARIANT PHP1A GLY-280.
RX   PubMed=11926205; DOI=10.1515/JPEM.2002.15.3.259;
RA   Lim S.H., Poh L.K., Cowell C.T., Tey B.H., Loke K.Y.;
RT   "Mutational analysis of the GNAS1 exons encoding the stimulatory G
RT   protein in five patients with pseudohypoparathyroidism type 1a.";
RL   J. Pediatr. Endocrinol. Metab. 15:259-268(2002).
RN   [43]
RP   INVOLVEMENT IN PHP1B.
RX   PubMed=12858292; DOI=10.1086/377136;
RA   Jan de Beur S., Ding C., Germain-Lee E., Cho J., Maret A.,
RA   Levine M.A.;
RT   "Discordance between genetic and epigenetic defects in
RT   pseudohypoparathyroidism type 1b revealed by inconsistent loss of
RT   maternal imprinting at GNAS1.";
RL   Am. J. Hum. Genet. 73:314-322(2003).
RN   [44]
RP   VARIANTS AHO ILE-242; SER-246 AND VAL-259.
RX   PubMed=12624854; DOI=10.1086/374566;
RA   Rickard S.J., Wilson L.C.;
RT   "Analysis of GNAS1 and overlapping transcripts identifies the parental
RT   origin of mutations in patients with sporadic Albright hereditary
RT   osteodystrophy and reveals a model system in which to observe the
RT   effects of splicing mutations on translated and untranslated messenger
RT   RNA.";
RL   Am. J. Hum. Genet. 72:961-974(2003).
RN   [45]
RP   VARIANT PHP1A ASN-338.
RX   PubMed=12656668; DOI=10.1530/eje.0.1480463;
RA   Pohlenz J., Ahrens W., Hiort O.;
RT   "A new heterozygous mutation (L338N) in the human Gsalpha (GNAS1) gene
RT   as a cause for congenital hypothyroidism in Albright's hereditary
RT   osteodystrophy.";
RL   Eur. J. Endocrinol. 148:463-468(2003).
RN   [46]
RP   VARIANTS AIMAH1 HIS-201 AND SER-201.
RX   PubMed=12727968; DOI=10.1210/jc.2002-021362;
RA   Fragoso M.C.B.V., Domenice S., Latronico A.C., Martin R.M.,
RA   Pereira M.A.A., Zerbini M.C.N., Lucon A.M., Mendonca B.B.;
RT   "Cushing's syndrome secondary to adrenocorticotropin-independent
RT   macronodular adrenocortical hyperplasia due to activating mutations of
RT   GNAS1 gene.";
RL   J. Clin. Endocrinol. Metab. 88:2147-2151(2003).
RN   [47]
RP   INVOLVEMENT IN PHP1B.
RX   PubMed=14561710; DOI=10.1172/JCI19159;
RA   Bastepe M., Froehlich L.F., Hendy G.N., Indridason O.S., Josse R.G.,
RA   Koshiyama H., Koerkkoe J., Nakamoto J.M., Rosenbloom A.L.,
RA   Slyper A.H., Sugimoto T., Tsatsoulis A., Crawford J.D., Jueppner H.;
RT   "Autosomal dominant pseudohypoparathyroidism type Ib is associated
RT   with a heterozygous microdeletion that likely disrupts a putative
RT   imprinting control element of GNAS.";
RL   J. Clin. Invest. 112:1255-1263(2003).
RN   [48]
RP   VARIANT POH ARG-281.
RX   PubMed=14723729; DOI=10.1111/j.1365-2230.2004.01439.x;
RA   Chan I., Hamada T., Hardman C., McGrath J.A., Child F.J.;
RT   "Progressive osseous heteroplasia resulting from a new mutation in the
RT   GNAS1 gene.";
RL   Clin. Exp. Dermatol. 29:77-80(2004).
RN   [49]
RP   INVOLVEMENT IN PHP1B.
RX   PubMed=15800843; DOI=10.1086/429932;
RA   Linglart A., Gensure R.C., Olney R.C., Jueppner H., Bastepe M.;
RT   "A novel STX16 deletion in autosomal dominant pseudohypoparathyroidism
RT   type Ib redefines the boundaries of a cis-acting imprinting control
RT   element of GNAS.";
RL   Am. J. Hum. Genet. 76:804-814(2005).
RN   [50]
RP   VARIANT AHO/PHP1A SER-106.
RX   PubMed=15817905; DOI=10.1530/eje.1.01879;
RA   Riepe F.G., Ahrens W., Krone N., Foelster-Holst R., Brasch J.,
RA   Sippell W.G., Hiort O., Partsch C.-J.;
RT   "Early manifestation of calcinosis cutis in pseudohypoparathyroidism
RT   type Ia associated with a novel mutation in the GNAS gene.";
RL   Eur. J. Endocrinol. 152:515-519(2005).
RN   [51]
RP   INVOLVEMENT IN PHP1B.
RX   PubMed=15592469; DOI=10.1038/ng1487;
RA   Bastepe M., Froehlich L.F., Linglart A., Abu-Zahra H.S., Tojo K.,
RA   Ward L.M., Jueppner H.;
RT   "Deletion of the NESP55 differentially methylated region causes loss
RT   of maternal GNAS imprints and pseudohypoparathyroidism type Ib.";
RL   Nat. Genet. 37:25-27(2005).
RN   [52]
RP   VARIANTS PHP1C ARG-388 AND LYS-392, CHARACTERIZATION OF VARIANTS PHP1C
RP   ARG-388 AND LYS-392, AND FUNCTION.
RX   PubMed=21488135; DOI=10.1002/humu.21489;
RA   Thiele S., de Sanctis L., Werner R., Grotzinger J., Aydin C.,
RA   Juppner H., Bastepe M., Hiort O.;
RT   "Functional characterization of GNAS mutations found in patients with
RT   pseudohypoparathyroidism type Ic defines a new subgroup of
RT   pseudohypoparathyroidism affecting selectively Gsalpha-receptor
RT   interaction.";
RL   Hum. Mutat. 32:653-660(2011).
CC   -!- FUNCTION: Guanine nucleotide-binding proteins (G proteins)
CC       function as transducers in numerous signaling pathways controlled
CC       by G protein-coupled receptors (GPCRs) (PubMed:17110384).
CC       Signaling involves the activation of adenylyl cyclases, resulting
CC       in increased levels of the signaling molecule cAMP
CC       (PubMed:26206488, PubMed:8702665). GNAS functions downstream of
CC       several GPCRs, including beta-adrenergic receptors
CC       (PubMed:21488135). Stimulates the Ras signaling pathway via
CC       RAPGEF2 (PubMed:12391161). {ECO:0000269|PubMed:12391161,
CC       ECO:0000269|PubMed:17110384, ECO:0000269|PubMed:21488135,
CC       ECO:0000269|PubMed:26206488, ECO:0000269|PubMed:8702665}.
CC   -!- SUBUNIT: Heterotrimeric G proteins are composed of 3 units; alpha,
CC       beta and gamma. The alpha chain contains the guanine nucleotide
CC       binding site. Interacts with CRY1; the interaction may block GPCR-
CC       mediated regulation of cAMP concentrations (PubMed:20852621).
CC       Interacts with ADCY5 and stimulates its adenylyl cyclase activity
CC       (PubMed:17110384, PubMed:26206488). Interacts with ADCY6 and
CC       stimulates its adenylyl cyclase activity (PubMed:17110384).
CC       Interacts with ADCY2 (By similarity).
CC       {ECO:0000250|UniProtKB:P04896, ECO:0000269|PubMed:17110384,
CC       ECO:0000269|PubMed:20852621}.
CC   -!- INTERACTION:
CC       O89053:Coro1a (xeno); NbExp=2; IntAct=EBI-1047114, EBI-6665847;
CC       P42866:Oprm1 (xeno); NbExp=2; IntAct=EBI-7607528, EBI-5282656;
CC   -!- SUBCELLULAR LOCATION: Cell membrane
CC       {ECO:0000250|UniProtKB:P63094}; Lipid-anchor
CC       {ECO:0000250|UniProtKB:P63094}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=8;
CC       Name=Gnas-1; Synonyms=Alpha-S2, GNASl, Alpha-S-long;
CC         IsoId=P63092-1, P04895-1;
CC         Sequence=Displayed;
CC       Name=Gnas-2; Synonyms=Alpha-S1, GNASs, Alpha-S-short;
CC         IsoId=P63092-2, P04895-2;
CC         Sequence=VSP_001833, VSP_001834;
CC       Name=3;
CC         IsoId=P63092-3; Sequence=VSP_026616, VSP_026617;
CC         Note=No experimental confirmation available.;
CC       Name=XLas-1;
CC         IsoId=Q5JWF2-1; Sequence=External;
CC         Note=Gene prediction confirmed by EST data.;
CC       Name=XLas-2;
CC         IsoId=Q5JWF2-2; Sequence=External;
CC         Note=Gene prediction confirmed by EST data.;
CC       Name=XLas-3;
CC         IsoId=Q5JWF2-3; Sequence=External;
CC       Name=Nesp55;
CC         IsoId=O95467-1; Sequence=External;
CC         Note=Shares no sequence similarity with other isoforms due to a
CC         novel first exon containing the entire reading frame spliced to
CC         shared exon 2 so that exons 2-13 make up the 3'-UTR.;
CC       Name=4;
CC         IsoId=P63092-4; Sequence=VSP_047325;
CC         Note=Gene prediction based on EST data.;
CC   -!- DISEASE: Albright hereditary osteodystrophy (AHO) [MIM:103580]: A
CC       disorder characterized by short stature, obesity, round facies,
CC       brachydactyly and subcutaneous calcification. It is often
CC       associated with pseudohypoparathyoidism, hypocalcemia and elevated
CC       PTH levels. {ECO:0000269|PubMed:11450852,
CC       ECO:0000269|PubMed:11600516, ECO:0000269|PubMed:12624854,
CC       ECO:0000269|PubMed:15817905, ECO:0000269|PubMed:7523385,
CC       ECO:0000269|PubMed:8388883, ECO:0000269|PubMed:9328353,
CC       ECO:0000269|PubMed:9727013}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Pseudohypoparathyroidism 1A (PHP1A) [MIM:103580]: A
CC       disorder characterized by end-organ resistance to parathyroid
CC       hormone, hypocalcemia and hyperphosphatemia. It is commonly
CC       associated with Albright hereditary osteodystrophy whose features
CC       are short stature, obesity, round facies, short metacarpals and
CC       ectopic calcification. {ECO:0000269|PubMed:11788646,
CC       ECO:0000269|PubMed:11926205, ECO:0000269|PubMed:12656668}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: McCune-Albright syndrome (MAS) [MIM:174800]:
CC       Characterized by polyostotic fibrous dysplasia, cafe-au-lait
CC       lesions, and a variety of endocrine disorders, including
CC       precocious puberty, hyperthyroidism, hypercortisolism, growth
CC       hormone excess, and hyperprolactinemia. The mutations producing
CC       MAS lead to constitutive activation of GS alpha.
CC       {ECO:0000269|PubMed:10571700, ECO:0000269|PubMed:1594625,
CC       ECO:0000269|PubMed:1944469, ECO:0000269|PubMed:7751320}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Pituitary adenoma, growth hormone-secreting, 1 (PAGH1)
CC       [MIM:102200]: A growth hormone-secreting, benign neoplasm of the
CC       anterior pituitary gland, also known as somatotropinoma. It
CC       clinically results in acromegaly, a condition characterized by
CC       coarse facial features, protruding jaw, and enlarged extremities.
CC       Excessive production of growth hormone in children or adolescents
CC       before the closure of epiphyses causes gigantism, a condition
CC       characterized by abnormally tall stature. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Progressive osseous heteroplasia (POH) [MIM:166350]: Rare
CC       autosomal dominant disorder characterized by extensive dermal
CC       ossification during childhood, followed by disabling and
CC       widespread heterotopic ossification of skeletal muscle and deep
CC       connective tissue. {ECO:0000269|PubMed:14723729}. Note=The disease
CC       is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: ACTH-independent macronodular adrenal hyperplasia 1
CC       (AIMAH1) [MIM:219080]: A rare adrenal defect characterized by
CC       multiple, bilateral, non-pigmented, benign, adrenocortical
CC       nodules. It results in excessive production of cortisol leading to
CC       ACTH-independent Cushing syndrome. Clinical manifestations of
CC       Cushing syndrome include facial and truncal obesity, abdominal
CC       striae, muscular weakness, osteoporosis, arterial hypertension,
CC       diabetes. {ECO:0000269|PubMed:12727968}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Pseudohypoparathyroidism 1B (PHP1B) [MIM:603233]: A
CC       disorder characterized by end-organ resistance to parathyroid
CC       hormone, hypocalcemia and hyperphosphatemia. Patients affected
CC       with PHP1B lack developmental defects characteristic of Albright
CC       hereditary osteodystrophy, and typically show no other endocrine
CC       abnormalities besides resistance to PTH.
CC       {ECO:0000269|PubMed:11029463, ECO:0000269|PubMed:11067869,
CC       ECO:0000269|PubMed:11294659, ECO:0000269|PubMed:12858292,
CC       ECO:0000269|PubMed:14561710, ECO:0000269|PubMed:15592469,
CC       ECO:0000269|PubMed:15800843}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry. Most
CC       affected individuals have defects in methylation of the gene. In
CC       some cases microdeletions involving the STX16 appear to cause loss
CC       of methylation at exon A/B of GNAS, resulting in PHP1B. Paternal
CC       uniparental isodisomy have also been observed.
CC   -!- DISEASE: GNAS hyperfunction (GNASHYP) [MIM:139320]: This condition
CC       is characterized by increased trauma-related bleeding tendency,
CC       prolonged bleeding time, brachydactyly and mental retardation.
CC       Both the XLas isoforms and the ALEX protein are mutated which
CC       strongly reduces the interaction between them and this may allow
CC       unimpeded activation of the XLas isoforms. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Pseudohypoparathyroidism 1C (PHP1C) [MIM:612462]: A
CC       disorder characterized by end-organ resistance to parathyroid
CC       hormone, hypocalcemia and hyperphosphatemia. It is commonly
CC       associated with Albright hereditary osteodystrophy whose features
CC       are short stature, obesity, round facies, short metacarpals and
CC       ectopic calcification. {ECO:0000269|PubMed:21488135}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- MISCELLANEOUS: This protein is produced by a bicistronic gene
CC       which also produces the ALEX protein from an overlapping reading
CC       frame.
CC   -!- MISCELLANEOUS: The GNAS locus is imprinted in a complex manner,
CC       giving rise to distinct paternally, maternally and biallelically
CC       expressed proteins. The XLas isoforms are paternally derived, the
CC       Gnas isoforms are biallelically derived and the Nesp55 isoforms
CC       are maternally derived.
CC   -!- SIMILARITY: Belongs to the G-alpha family. G(s) subfamily.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X04408; CAA27996.1; -; mRNA.
DR   EMBL; X04409; CAA27997.1; -; mRNA.
DR   EMBL; M21142; AAA53147.1; -; Genomic_DNA.
DR   EMBL; M21139; AAA53147.1; JOINED; Genomic_DNA.
DR   EMBL; M21740; AAA53147.1; JOINED; Genomic_DNA.
DR   EMBL; M21140; AAA53147.1; JOINED; Genomic_DNA.
DR   EMBL; M21741; AAA53147.1; JOINED; Genomic_DNA.
DR   EMBL; M21141; AAA53147.1; JOINED; Genomic_DNA.
DR   EMBL; M21142; AAA53146.1; -; Genomic_DNA.
DR   EMBL; M21139; AAA53146.1; JOINED; Genomic_DNA.
DR   EMBL; M21740; AAA53146.1; JOINED; Genomic_DNA.
DR   EMBL; M21140; AAA53146.1; JOINED; Genomic_DNA.
DR   EMBL; M21741; AAA53146.1; JOINED; Genomic_DNA.
DR   EMBL; M21141; AAA53146.1; JOINED; Genomic_DNA.
DR   EMBL; M21142; AAA53148.1; -; Genomic_DNA.
DR   EMBL; M21139; AAA53148.1; JOINED; Genomic_DNA.
DR   EMBL; M21141; AAA53148.1; JOINED; Genomic_DNA.
DR   EMBL; M21740; AAA53148.1; JOINED; Genomic_DNA.
DR   EMBL; M21741; AAA53148.1; JOINED; Genomic_DNA.
DR   EMBL; M21142; AAA53149.1; -; Genomic_DNA.
DR   EMBL; M21139; AAA53149.1; JOINED; Genomic_DNA.
DR   EMBL; M21740; AAA53149.1; JOINED; Genomic_DNA.
DR   EMBL; M21741; AAA53149.1; JOINED; Genomic_DNA.
DR   EMBL; M21141; AAA53149.1; JOINED; Genomic_DNA.
DR   EMBL; U12466; AAB60334.2; -; Genomic_DNA.
DR   EMBL; X07036; CAA30084.1; -; mRNA.
DR   EMBL; AF493897; AAM12611.1; -; mRNA.
DR   EMBL; AF493898; AAM12612.1; -; mRNA.
DR   EMBL; BT009905; AAP88907.1; -; mRNA.
DR   EMBL; AL109840; CAI42914.1; -; Genomic_DNA.
DR   EMBL; AL121917; CAI42914.1; JOINED; Genomic_DNA.
DR   EMBL; AL109840; CAI42915.1; -; Genomic_DNA.
DR   EMBL; AL121917; CAI42915.1; JOINED; Genomic_DNA.
DR   EMBL; AL109840; CAI42916.1; -; Genomic_DNA.
DR   EMBL; AL121917; CAI42916.1; JOINED; Genomic_DNA.
DR   EMBL; AL109840; CAI42917.1; -; Genomic_DNA.
DR   EMBL; AL121917; CAI42917.1; JOINED; Genomic_DNA.
DR   EMBL; AL121917; CAI42546.1; -; Genomic_DNA.
DR   EMBL; AL109840; CAI42546.1; JOINED; Genomic_DNA.
DR   EMBL; AL121917; CAI42547.1; -; Genomic_DNA.
DR   EMBL; AL109840; CAI42547.1; JOINED; Genomic_DNA.
DR   EMBL; AL121917; CAI42548.1; -; Genomic_DNA.
DR   EMBL; AL109840; CAI42548.1; JOINED; Genomic_DNA.
DR   EMBL; AL121917; CAI42549.1; -; Genomic_DNA.
DR   EMBL; AL109840; CAI42549.1; JOINED; Genomic_DNA.
DR   EMBL; AL132655; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471077; EAW75468.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW75460.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW75463.1; -; Genomic_DNA.
DR   EMBL; BC002722; AAH02722.1; -; mRNA.
DR   EMBL; BC008855; AAH08855.1; -; mRNA.
DR   EMBL; BC066923; AAH66923.1; -; mRNA.
DR   EMBL; BC022875; AAH22875.1; -; mRNA.
DR   EMBL; BC104928; AAI04929.1; -; mRNA.
DR   EMBL; BC108315; AAI08316.2; -; mRNA.
DR   EMBL; M14631; AAA52583.1; -; mRNA.
DR   CCDS; CCDS13472.1; -.
DR   CCDS; CCDS42892.1; -. [P63092-3]
DR   CCDS; CCDS46623.1; -. [P63092-4]
DR   CCDS; CCDS46624.1; -. [P63092-2]
DR   PIR; B31927; RGHUA2.
DR   PIR; C31927; RGHUA1.
DR   RefSeq; NP_000507.1; NM_000516.5. [P63092-1]
DR   RefSeq; NP_001070956.1; NM_001077488.3. [P63092-4]
DR   RefSeq; NP_001070957.1; NM_001077489.3. [P63092-3]
DR   RefSeq; NP_001070958.1; NM_001077490.2.
DR   RefSeq; NP_001296769.1; NM_001309840.1.
DR   RefSeq; NP_536350.2; NM_080425.3.
DR   RefSeq; NP_536351.1; NM_080426.3. [P63092-2]
DR   UniGene; Hs.125898; -.
DR   ProteinModelPortal; P63092; -.
DR   SMR; P63092; 39-388.
DR   BioGrid; 109040; 84.
DR   IntAct; P63092; 22.
DR   MINT; MINT-262348; -.
DR   STRING; 9606.ENSP00000360141; -.
DR   ChEMBL; CHEMBL4377; -.
DR   iPTMnet; P63092; -.
DR   SwissPalm; P63092; -.
DR   BioMuta; NPEPL1; -.
DR   DMDM; 52000961; -.
DR   EPD; P63092; -.
DR   PaxDb; P63092; -.
DR   PeptideAtlas; P63092; -.
DR   PRIDE; P63092; -.
DR   DNASU; 2778; -.
DR   Ensembl; ENST00000265620; ENSP00000265620; ENSG00000087460. [P63092-3]
DR   Ensembl; ENST00000354359; ENSP00000346328; ENSG00000087460. [P63092-4]
DR   Ensembl; ENST00000371085; ENSP00000360126; ENSG00000087460. [P63092-1]
DR   Ensembl; ENST00000371095; ENSP00000360136; ENSG00000087460. [P63092-2]
DR   GeneID; 2778; -.
DR   KEGG; hsa:2778; -.
DR   UCSC; uc002yaa.4; human.
DR   CTD; 2778; -.
DR   GeneCards; GNAS; -.
DR   HGNC; HGNC:4392; GNAS.
DR   HPA; CAB010337; -.
DR   MalaCards; GNAS; -.
DR   MIM; 102200; phenotype.
DR   MIM; 103580; phenotype.
DR   MIM; 139320; gene+phenotype.
DR   MIM; 166350; phenotype.
DR   MIM; 174800; phenotype.
DR   MIM; 219080; phenotype.
DR   MIM; 603233; phenotype.
DR   MIM; 612462; phenotype.
DR   neXtProt; NX_P63092; -.
DR   Orphanet; 562; McCune-Albright syndrome.
DR   Orphanet; 93277; Monostotic fibrous dysplasia.
DR   Orphanet; 93276; Polyostotic fibrous dysplasia.
DR   Orphanet; 2762; Progressive osseous heteroplasia.
DR   Orphanet; 79443; Pseudohypoparathyroidism type 1A.
DR   Orphanet; 94089; Pseudohypoparathyroidism type 1B.
DR   Orphanet; 79444; Pseudohypoparathyroidism type 1C.
DR   Orphanet; 79445; Pseudopseudohypoparathyroidism.
DR   PharmGKB; PA175; -.
DR   eggNOG; KOG0099; Eukaryota.
DR   eggNOG; ENOG410XPC4; LUCA.
DR   GeneTree; ENSGT00770000120503; -.
DR   HOGENOM; HOG000038729; -.
DR   HOVERGEN; HBG063184; -.
DR   KO; K04632; -.
DR   OMA; YEHTKTL; -.
DR   Reactome; R-HSA-163359; Glucagon signaling in metabolic regulation.
DR   Reactome; R-HSA-164378; PKA activation in glucagon signalling.
DR   Reactome; R-HSA-381676; Glucagon-like Peptide-1 (GLP1) regulates insulin secretion.
DR   Reactome; R-HSA-392851; Prostacyclin signalling through prostacyclin receptor.
DR   Reactome; R-HSA-418555; G alpha (s) signalling events.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   Reactome; R-HSA-418597; G alpha (z) signalling events.
DR   Reactome; R-HSA-420092; Glucagon-type ligand receptors.
DR   Reactome; R-HSA-432040; Vasopressin regulates renal water homeostasis via Aquaporins.
DR   Reactome; R-HSA-5610787; Hedgehog 'off' state.
DR   SIGNOR; P63092; -.
DR   ChiTaRS; GNAS; human.
DR   GenomeRNAi; 2778; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   Bgee; ENSG00000087460; -.
DR   CleanEx; HS_GNAS; -.
DR   ExpressionAtlas; P63092; baseline and differential.
DR   Genevisible; P63092; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:LIFEdb.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005834; C:heterotrimeric G-protein complex; TAS:UniProtKB.
DR   GO; GO:0031224; C:intrinsic component of membrane; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:UniProtKB.
DR   GO; GO:0032588; C:trans-Golgi network membrane; IDA:UniProtKB.
DR   GO; GO:0005525; F:GTP binding; IEA:UniProtKB-KW.
DR   GO; GO:0003924; F:GTPase activity; TAS:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004871; F:signal transducer activity; IDA:UniProtKB.
DR   GO; GO:0007190; P:activation of adenylate cyclase activity; TAS:UniProtKB.
DR   GO; GO:0071880; P:adenylate cyclase-activating adrenergic receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007191; P:adenylate cyclase-activating dopamine receptor signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0007189; P:adenylate cyclase-activating G-protein coupled receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0060348; P:bone development; IDA:UniProtKB.
DR   GO; GO:0071870; P:cellular response to catecholamine stimulus; ISS:BHF-UCL.
DR   GO; GO:0071377; P:cellular response to glucagon stimulus; TAS:Reactome.
DR   GO; GO:0071380; P:cellular response to prostaglandin E stimulus; ISS:BHF-UCL.
DR   GO; GO:0050890; P:cognition; IDA:UniProtKB.
DR   GO; GO:0048589; P:developmental growth; IDA:UniProtKB.
DR   GO; GO:0060789; P:hair follicle placode formation; IDA:UniProtKB.
DR   GO; GO:0046907; P:intracellular transport; NAS:UniProtKB.
DR   GO; GO:0070527; P:platelet aggregation; IDA:UniProtKB.
DR   GO; GO:0030819; P:positive regulation of cAMP biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0043950; P:positive regulation of cAMP-mediated signaling; IDA:UniProtKB.
DR   GO; GO:0043547; P:positive regulation of GTPase activity; IDA:UniProtKB.
DR   GO; GO:0050796; P:regulation of insulin secretion; TAS:Reactome.
DR   GO; GO:0003091; P:renal water homeostasis; TAS:Reactome.
DR   GO; GO:0007608; P:sensory perception of smell; TAS:UniProtKB.
DR   Gene3D; 1.10.400.10; -; 1.
DR   Gene3D; 3.40.50.300; -; 2.
DR   InterPro; IPR000367; Gprotein_alpha_S.
DR   InterPro; IPR001019; Gprotein_alpha_su.
DR   InterPro; IPR011025; GproteinA_insert.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   PANTHER; PTHR10218; PTHR10218; 2.
DR   Pfam; PF00503; G-alpha; 1.
DR   PRINTS; PR00318; GPROTEINA.
DR   PRINTS; PR00443; GPROTEINAS.
DR   SMART; SM00275; G_alpha; 1.
DR   SUPFAM; SSF47895; SSF47895; 1.
DR   SUPFAM; SSF52540; SSF52540; 2.
PE   1: Evidence at protein level;
KW   ADP-ribosylation; Alternative splicing; Cell membrane;
KW   Complete proteome; Cushing syndrome; Direct protein sequencing;
KW   Disease mutation; GTP-binding; Isopeptide bond; Lipoprotein;
KW   Magnesium; Membrane; Metal-binding; Nucleotide-binding; Obesity;
KW   Palmitate; Phosphoprotein; Polymorphism; Proto-oncogene;
KW   Reference proteome; Transducer; Ubl conjugation.
FT   CHAIN         1    394       Guanine nucleotide-binding protein G(s)
FT                                subunit alpha isoforms short.
FT                                /FTId=PRO_0000203721.
FT   NP_BIND      47     55       GTP. {ECO:0000250|UniProtKB:P04896}.
FT   NP_BIND     197    204       GTP. {ECO:0000250|UniProtKB:P04896}.
FT   NP_BIND     223    227       GTP. {ECO:0000250|UniProtKB:P04896}.
FT   NP_BIND     292    295       GTP. {ECO:0000250|UniProtKB:P04896}.
FT   METAL        54     54       Magnesium.
FT                                {ECO:0000250|UniProtKB:P04896}.
FT   METAL       204    204       Magnesium.
FT                                {ECO:0000250|UniProtKB:P04896}.
FT   BINDING     366    366       GTP; via amide nitrogen.
FT                                {ECO:0000250|UniProtKB:P04896}.
FT   MOD_RES     201    201       ADP-ribosylarginine; by cholera toxin.
FT                                {ECO:0000250}.
FT   MOD_RES     352    352       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   LIPID         2      2       N-palmitoyl glycine.
FT                                {ECO:0000250|UniProtKB:P04896}.
FT   LIPID         3      3       S-palmitoyl cysteine.
FT                                {ECO:0000269|PubMed:21044946}.
FT   CROSSLNK    300    300       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT   VAR_SEQ      71     72       EG -> DS (in isoform Gnas-2).
FT                                {ECO:0000303|PubMed:3093273,
FT                                ECO:0000303|Ref.4}.
FT                                /FTId=VSP_001833.
FT   VAR_SEQ      71     71       E -> D (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_026616.
FT   VAR_SEQ      72     86       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_026617.
FT   VAR_SEQ      73     86       Missing (in isoform Gnas-2).
FT                                {ECO:0000303|PubMed:3093273,
FT                                ECO:0000303|Ref.4}.
FT                                /FTId=VSP_001834.
FT   VAR_SEQ      86     86       G -> GS (in isoform 4).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:3024154}.
FT                                /FTId=VSP_047325.
FT   VARIANT      99     99       L -> P (in AHO; dbSNP:rs137854531).
FT                                {ECO:0000269|PubMed:8388883}.
FT                                /FTId=VAR_003439.
FT   VARIANT     106    106       I -> S (in AHO/PHP1A).
FT                                {ECO:0000269|PubMed:15817905}.
FT                                /FTId=VAR_031872.
FT   VARIANT     115    115       P -> L (in AHO; dbSNP:rs137854539).
FT                                {ECO:0000269|PubMed:11600516}.
FT                                /FTId=VAR_017843.
FT   VARIANT     156    156       D -> N (in PHP1A).
FT                                {ECO:0000269|PubMed:11788646}.
FT                                /FTId=VAR_031873.
FT   VARIANT     159    159       V -> M (in PHP1A).
FT                                {ECO:0000269|PubMed:11788646}.
FT                                /FTId=VAR_031874.
FT   VARIANT     165    165       R -> C (in AHO; dbSNP:rs137854532).
FT                                {ECO:0000269|PubMed:8388883}.
FT                                /FTId=VAR_003440.
FT   VARIANT     201    201       R -> C (in MAS; also found in
FT                                somatotrophinoma; dbSNP:rs11554273).
FT                                {ECO:0000269|PubMed:1944469,
FT                                ECO:0000269|PubMed:2549426}.
FT                                /FTId=VAR_003442.
FT   VARIANT     201    201       R -> G (in MAS; dbSNP:rs11554273).
FT                                {ECO:0000269|PubMed:10571700}.
FT                                /FTId=VAR_017844.
FT   VARIANT     201    201       R -> H (in MAS and AIMAH1; also found in
FT                                somatotrophinoma; dbSNP:rs121913495).
FT                                {ECO:0000269|PubMed:12727968,
FT                                ECO:0000269|PubMed:1594625,
FT                                ECO:0000269|PubMed:1944469,
FT                                ECO:0000269|PubMed:2549426}.
FT                                /FTId=VAR_003441.
FT   VARIANT     201    201       R -> L (in non-MAS endocrine tumors).
FT                                {ECO:0000269|PubMed:7751320}.
FT                                /FTId=VAR_017845.
FT   VARIANT     201    201       R -> S (in AIMAH1; also found in
FT                                pituitary tumor and polyostotic fibrous
FT                                dysplasia; dbSNP:rs11554273).
FT                                {ECO:0000269|PubMed:12727968,
FT                                ECO:0000269|PubMed:8766942,
FT                                ECO:0000269|PubMed:9267696}.
FT                                /FTId=VAR_017846.
FT   VARIANT     227    227       Q -> H (in pituitary adenomas; also found
FT                                in a patient with severe Cushing
FT                                syndrome; dbSNP:rs137854533).
FT                                {ECO:0000269|PubMed:7737262}.
FT                                /FTId=VAR_017847.
FT   VARIANT     227    227       Q -> R (in somatotrophinoma;
FT                                dbSNP:rs121913494).
FT                                {ECO:0000269|PubMed:2549426}.
FT                                /FTId=VAR_003443.
FT   VARIANT     231    231       R -> H (in AHO; impairs the ability to
FT                                mediate hormonal stimulation;
FT                                dbSNP:rs137854538).
FT                                {ECO:0000269|PubMed:11450852,
FT                                ECO:0000269|PubMed:8702665,
FT                                ECO:0000269|PubMed:9159128}.
FT                                /FTId=VAR_017848.
FT   VARIANT     242    242       T -> I (in AHO).
FT                                {ECO:0000269|PubMed:12624854}.
FT                                /FTId=VAR_031875.
FT   VARIANT     246    246       F -> S (in AHO).
FT                                {ECO:0000269|PubMed:12624854}.
FT                                /FTId=VAR_031876.
FT   VARIANT     250    250       S -> R (in AHO; may alter guanine
FT                                nucleotide binding which could lead to
FT                                thermolability and impaired function;
FT                                dbSNP:rs137854534).
FT                                {ECO:0000269|PubMed:9328353}.
FT                                /FTId=VAR_017849.
FT   VARIANT     258    258       R -> W (in AHO; defective GDP binding
FT                                resulting in increased thermolability and
FT                                decreased activation; dbSNP:rs137854535).
FT                                {ECO:0000269|PubMed:9727013}.
FT                                /FTId=VAR_015388.
FT   VARIANT     259    259       E -> V (in AHO).
FT                                {ECO:0000269|PubMed:12624854}.
FT                                /FTId=VAR_031877.
FT   VARIANT     280    280       R -> G (in PHP1A).
FT                                {ECO:0000269|PubMed:11926205}.
FT                                /FTId=VAR_031878.
FT   VARIANT     280    280       R -> K (in PHP1A).
FT                                {ECO:0000269|PubMed:11788646}.
FT                                /FTId=VAR_031879.
FT   VARIANT     281    281       W -> R (in POH).
FT                                {ECO:0000269|PubMed:14723729}.
FT                                /FTId=VAR_031880.
FT   VARIANT     338    338       K -> N (in PHP1A).
FT                                {ECO:0000269|PubMed:12656668}.
FT                                /FTId=VAR_031881.
FT   VARIANT     366    366       A -> S (in PHP1A; the patient also shows
FT                                testotoxicosis; constitutively activates
FT                                adenylyl cyclase in vitro; rapidly
FT                                degraded at 37 degrees resulting in loss
FT                                of Gs activity; dbSNP:rs137854537).
FT                                {ECO:0000269|PubMed:8072545}.
FT                                /FTId=VAR_017850.
FT   VARIANT     380    380       R -> L (in dbSNP:rs8986).
FT                                /FTId=VAR_049358.
FT   VARIANT     382    382       Missing (unable to interact with the
FT                                receptor for PTH).
FT                                {ECO:0000269|PubMed:11029463}.
FT                                /FTId=VAR_034744.
FT   VARIANT     385    385       R -> H (in AHO; uncouples receptors from
FT                                adenylyl cyclases).
FT                                {ECO:0000269|PubMed:7523385}.
FT                                /FTId=VAR_003444.
FT   VARIANT     388    388       L -> R (in PHP1C; significantly reduces
FT                                receptor-mediated activation; displays
FT                                normal receptor-independent activation;
FT                                dbSNP:rs397514457).
FT                                {ECO:0000269|PubMed:21488135}.
FT                                /FTId=VAR_066387.
FT   VARIANT     392    392       E -> K (in PHP1C; significantly reduces
FT                                receptor-mediated activation; displays
FT                                normal receptor-independent activation;
FT                                dbSNP:rs397514456).
FT                                {ECO:0000269|PubMed:21488135}.
FT                                /FTId=VAR_066388.
FT   MUTAGEN     170    170       Q->A: Increases GDP release but does not
FT                                affect receptor-mediated activation.
FT                                {ECO:0000269|PubMed:10200251}.
FT   MUTAGEN     258    258       R->A: Increases GDP release and impairs
FT                                receptor-mediated activation; markedly
FT                                elevated intrinsic GTPase rate which will
FT                                lead to more rapid inactivation.
FT                                {ECO:0000269|PubMed:10200251,
FT                                ECO:0000269|PubMed:9727013}.
FT   CONFLICT      3      3       C -> Y (in Ref. 8; AAH66923).
FT                                {ECO:0000305}.
FT   CONFLICT      6      6       N -> T (in Ref. 3; CAA30084).
FT                                {ECO:0000305}.
FT   CONFLICT     72     72       Missing (in Ref. 8; AAH66923).
FT                                {ECO:0000305}.
FT   CONFLICT    167    167       N -> D (in Ref. 8; AAH22875).
FT                                {ECO:0000305}.
FT   CONFLICT    230    230       E -> Q (in Ref. 9; AAA52583).
FT                                {ECO:0000305}.
SQ   SEQUENCE   394 AA;  45665 MW;  CD541181FC4412EF CRC64;
     MGCLGNSKTE DQRNEEKAQR EANKKIEKQL QKDKQVYRAT HRLLLLGAGE SGKSTIVKQM
     RILHVNGFNG EGGEEDPQAA RSNSDGEKAT KVQDIKNNLK EAIETIVAAM SNLVPPVELA
     NPENQFRVDY ILSVMNVPDF DFPPEFYEHA KALWEDEGVR ACYERSNEYQ LIDCAQYFLD
     KIDVIKQADY VPSDQDLLRC RVLTSGIFET KFQVDKVNFH MFDVGGQRDE RRKWIQCFND
     VTAIIFVVAS SSYNMVIRED NQTNRLQEAL NLFKSIWNNR WLRTISVILF LNKQDLLAEK
     VLAGKSKIED YFPEFARYTT PEDATPEPGE DPRVTRAKYF IRDEFLRIST ASGDGRHYCY
     PHFTCAVDTE NIRRVFNDCR DIIQRMHLRQ YELL
//
